Not a good buy right now for an impatient buyer: near-term technicals lean bearish (MACD negative/expanding) and pattern-based odds point to further downside over the next month.
Upside case exists (Street is Overweight with ~$172–$175 targets), but the setup is not offering an immediate momentum edge; entry looks better after a confirmed rebound off support or a reclaim of key levels.
Trend/momentum: MACD histogram -0.65 below zero and negatively expanding → downside momentum still building.
RSI(6) 42.99 → neutral-to-weak (not oversold), leaving room for more downside before a high-probability bounce.
Moving averages: converging → consolidation, but with bearish momentum currently dominating.
Key levels: Pivot 152.869 is overhead resistance; nearest support S1 147.735 (then S2 144.563). A break/close below ~147.7 raises odds of a move toward mid-144s.
Market context: S&P 500 down ~0.48% on the day; not providing a supportive tailwind.
Quant/pattern read: expected drift is slightly negative (next day -0.11%, next week -0.8%, next month -3.26% bias).
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Put open interest (133) > call open interest (121) → mildly defensive positioning (OI put/call 1.1).
Activity: options volume is essentially zero today (calls 0, puts 0) → limited real-time conviction signal.
Volatility: IV(30d) ~43.78 vs historical vol ~31.36 → options implying elevated forward uncertainty; IV percentile ~41 (not extreme).
Technical Summary
Sell
0
Buy
14
Positive Catalysts
implying meaningful upside from ~$
Upcoming catalyst: QDEC 2025 earnings on 2026-02-26 after hours (Est. EPS 1.
could re-rate the stock if execution surprises to the upside.
Recent trend (2025-11-07): price targets were raised while maintaining Overweight ratings.
Piper Sandler: PT raised to $172 (from $153), Overweight; cited revenue upside across segments, margin outperformance, EPS beat, and higher guidance.
KeyBanc: PT raised to $175 (from $173), Overweight; encouraged by operational progress and higher 2025 EPS/EBITDA guidance despite macro headwinds.
Wall Street pros: improving execution/margins and guidance momentum; cons: macro headwinds and recent reported YoY revenue decline/loss quarter make the turnaround less linear.
Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 173.5 USD with a low forecast of 172 USD and a high forecast of 175 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ICUI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICUI is 173.5 USD with a low forecast of 172 USD and a high forecast of 175 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 149.640
Low
172
Averages
173.5
High
175
Current: 149.640
Low
172
Averages
173.5
High
175
Piper Sandler
Overweight
maintain
$153 -> $172
AI Analysis
2025-11-07
Reason
Piper Sandler
Price Target
$153 -> $172
AI Analysis
2025-11-07
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on ICU Medical to $172 from $153 and keeps an Overweight rating on the shares. The firm notes ICU reported Q3 results, including revenue upside across all segments, healthy margin outperformance, and a wide EPS beat. This contributed to management resetting EBITDA and EPS guidance meaningfully higher to account for the overage. Piper likes that the implied outlook for Q4 was prudently left unchanged.
KeyBanc
Overweight
maintain
$173 -> $175
2025-11-07
Reason
KeyBanc
Price Target
$173 -> $175
2025-11-07
maintain
Overweight
Reason
KeyBanc raised the firm's price target on ICU Medical to $175 from $173 on higher estimates, while keeping an Overweight rating on the shares. The firm remains encouraged by ICU's underlying operational progress as well as ability to raise 2025 EPS/EBITDA guidance, despite continued macro headwinds.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ICUI
